Biotech Specialty Pharma


4001 Miranda Avenue
Palo Alto, CA 94304 USA
Click for website

Research Sector Biotech Specialty Pharma

Summary Description Peptide-based drugs for kidney diseases and cancer.

Management Arlene M. Morris, President and Chief Executive Officer; Paul B. Cleveland, Chief Financial Officer and Executive Vice President; Anne-Marie Duliege, M.D., M.S., Chief Medical Officer; Jeffrey H. Knapp, Chief Commercial Officer; Kay Slocum, Senior Vice President, Human Resources

Click here for Financial Data
Keywords: hematide, hemoglobin, hronic renal failure, heart failure, inflammatory


Updated: Nov. 11, 2014


Affymax is developing a rich pipeline of synthetic peptide-based drugs against clinically validated targets for the treatment of kidney diseases and cancer.......view more

Products / Services

The company's lead productHematide is a synthetic peptide-based erythropoiesis-stimulating agent (ESA) in clinical development for anemia due to chronic kidney disease (CKD) and cancer. Hematide is in......view more

Technology / Differentiation

Affymax has amassed significant expertise in peptide drug discovery and development, including capabilities in creating long acting versions of drugs using PEGylation technology. While the companys c...view more